129 related articles for article (PubMed ID: 38807104)
1. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
He C; Mi X; Xu G; Xu X; Xin W; Zhong L; Zhu J; Shu Q; Fang L; Ding H
PLoS One; 2024; 19(5):e0302961. PubMed ID: 38748691
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma.
Gong J; Shang J; Su D; Qian X; Liu G; Sun Z
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):709-717. PubMed ID: 37190977
[TBL] [Abstract][Full Text] [Related]
7. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
Zheng Z; Chen H; Cai H; Zhu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):397-404. PubMed ID: 38031985
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
9. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Shi F; He Z; Su H; Wang L; Han S
Front Pharmacol; 2022; 13():961347. PubMed ID: 36467065
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
Zhou C; Wei J; Xu K; Lin Y; Zhang L; Li X
Risk Manag Healthc Policy; 2023; 16():2447-2458. PubMed ID: 38024498
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Yang F; Fu Y; Kumar A; Chen M; Si L; Rojanasarot S
Ann Transl Med; 2021 Aug; 9(15):1226. PubMed ID: 34532363
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Camrelizumab
Zhang Q; Wu P; He X; Ding Y; Shu Y
Front Oncol; 2021; 11():790373. PubMed ID: 34926306
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
Cai H; Xu B; Li N; Zheng B; Zheng Z; Liu M
Front Pharmacol; 2021; 12():732912. PubMed ID: 34867339
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Shao T; Ren Y; Zhao M; Tang W
Front Public Health; 2022; 10():912921. PubMed ID: 36045725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]